Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

ended September 30, 2008 were $45.4 million compared to $36.0 million for the period of 2007.

Research and development expenses for the three months ended September 30, 2008 totaled $10.1 million compared to $9.1 million for the three months ended September 30, 2007. Research and development expenses for the nine months ended September 30, 2008 totaled $32.6 million compared to $29.6 million for the same period of 2007. It is expected that total research and development expenses will remain constant over the next two years as the MAESTRO-01 and MINDSET-01 clinical trials near completion and MAESTRO-02 and MAESTRO-03 increase in number of patients under treatment. General and administrative expenses were $1.3 million for the three months ended September 30, 2008 compared to $1.1 million for the three months ended September 30, 2007. General and administrative expenses were $11.6 million for the nine months ended September 30, 2008 compared to $5.2 million for the same period of 2007.

As at September 30, 2008, cash and short-term investments totaled $98.8 million compared to $38.0 million at December 31, 2007. As at September 30, 2008, the Company had working capital of $94.0 million (excluding the current portion of deferred revenue which does not represent a cash obligation) compared to $34.8 million at December 31, 2007. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials for which it is responsible under the Lilly agreement.

As at September 30, 2008 there were 91,086,323 common shares, 26,021,528 warrants and 9,161,500 stock options of the Corporation issued and outstanding.

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... September 16, 2014 Cancer ... and Adoptive T-cell Therapies is a new market ... on the three principal types of therapeutics that ... development in cancer immunotherapy (which is often called ... vaccines and Adoptive cellular immunotherapy. , The ...
(Date:9/15/2014)... Sept. 15, 2014  FlexTech Alliance today issued ... printed product demonstrators (demos) and a functional electronic ... with pre-proposals due on October 22, 2014 and ... proposals ultimately selected are provided by the US ... cost share by the proposing organization. ...
(Date:9/15/2014)... a patient has sepsis, a life-threatening condition in which ... often too fast for antibiotics to help. A new ... a team at Harvard,s Wyss Institute for Biologically Inspired ... , "Even with the best current treatments, sepsis ... 30 percent of the time," said Mike Super, Ph.D., ...
(Date:9/15/2014)... of researchers led by Northeastern University has developed ... junctions and a variety of nanocarbon structures in ... easily scalable, which will allow the researchers to ... use in applications ranging from electronic devices to ... to sports equipment. , Their findings were published ...
Breaking Biology Technology:Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 2Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 3Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 4Cancer Immunotherapy Market: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies 5FlexTech Alliance Issues 2015 Request for Proposals in Flexible, Printed Electronics 2Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2
... Cambrex (NYSE:,CBM), a leading life sciences company, announced today ... and Chief Executive Officer,and a member of the Cambrex ... Mack, President and Chief Executive Officer since 1995,and Chairman ... Company will,separate the positions of Board Chairman and CEO ...
... PRINCETON, N.J., May 15 Derma Sciences, Inc.,(OTC Bulletin ... today for the first quarter ended March 31, 2008. ... previous year, including sales,from the newly acquired First Aid ... due primarily to higher than expected,integration costs associated with ...
... supply of top-quality custom cosmesis, hires U.S. ... sales and marketing ... /PRNewswire/ - Touch,Bionics, developer of the i-LIMB Hand, the world,s ... the complete operations of LIVINGSKIN, the developer of the unique,and ...
Cached Biology Technology:Cambrex Appoints Steven M. Klosk as President and CEO 2Derma Sciences Reports First Quarter 2008 Results 2Derma Sciences Reports First Quarter 2008 Results 3Derma Sciences Reports First Quarter 2008 Results 4Derma Sciences Reports First Quarter 2008 Results 5Touch Bionics acquires LIVINGSKIN 2Touch Bionics acquires LIVINGSKIN 3
(Date:9/15/2014)... naturally across all kingdoms of life and constitute a ... of biological activities. The presence of halogen substituents in ... molecular properties. , One of the Holy ... late-stage, site-specific incorporation of a halogen atom into a ... (one of the most inert chemical bonds known in ...
(Date:9/15/2014)... Australia,s leading coral reef ecologists fears that reef biodiversity ... survival that we once thought. , In an international ... Centre of Excellence for Coral Reef Studies (Coral CoE) ... important species within reef ecosystems. , In coral reefs, ... jobs that keep the ecosystem safe and functioning. ...
(Date:9/15/2014)... of Science and Technology in Society in the College ... has won a 2014 National Science Foundation Faculty Early ... of creating a global nuclear emergency response plan. , ... Plant in March 2011 was a turning point in ... Three of the plant,s six nuclear reactors melted down ...
Breaking Biology News(10 mins):Pitt chemical biologist finds new halogenation enzyme 2Specialized species critical for reefs 2'Nuclear disasters don't respect national boundaries' 2
... State University have discovered a new method to speed ... advance that could play an important role in making ... an arrayed microchannel reactor and a "laminated architecture" in ... them, are stacked in parallel to provide a high ...
... the first time, completely characterized an important chemical reaction that ... areas. The team,s results indicate that computer models may be ... air quality (smoggy days) by as much as five to ... to people, animals and plants; is the primary ingredient of ...
... made by researchers at the Institut de recherches cliniques ... Noia, Director of the Mechanisms and Genetic Diversity research ... of Experimental Medicine . The team identified a mechanism ... the therapy of some types of lymphoma and leukemia. ...
Cached Biology News:Microreactor speeds nanotech particle production by 500 times 2Study improves accuracy of models for predicting ozone levels in urban areas 2Study improves accuracy of models for predicting ozone levels in urban areas 3Study improves accuracy of models for predicting ozone levels in urban areas 4A discovery could be important for the therapy of lymphoma and leukemia 2
... CLS number is a ... to easily match Cornings ... no availability yet, please ... Sigma-Aldrich number (Z71,515-8) or ...
...
... a fast, easy to use, reproducible and ... are 15 times faster and 5 times ... 5%). ,The VoluPAC tubes enable the determination ... a cell suspension, resulting in absolute data ...
... Maximize the value of your ... We offer the support you need ... using the most up to date ... with the Gene Expression Profiling Service ...
Biology Products: